Merck & Co., Inc. (MRK)
Will Merck's Keytruda Continue to Drive Growth Amid Looming LOE?
MRK leans on Keytruda for growth as exclusivity loss nears, with new combos and launches aiming to ease reliance.
Merck's cholesterol drug meets main goal in late-stage studies
Merck said on Monday its drug met the main goal of reducing a type of cholesterol in two late-stage studies.
MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study
Merck reports promising response rates for its ADC zilovertamab vedotin in relapsed DLBCL and KRAS inhibitor MK-1084 in solid tumors.
Merck Stock's Ticking Keytruda Time Bomb
Merck's (NYSE:MRK) top-selling drug – Keytruda's – impressive recent growth tells a compelling story, but it's one with a predictable ending. The pharmaceutical giant's remarkable performance is largely attributed to the phenomenal success of Keytruda, its blockbuster oncology drug.
Merck & Co., Inc. (MRK) Bernstein 41st Annual Strategic Decisions Conference (Transcript)
Merck & Co., Inc. (NYSE:MRK ) Bernstein 41st Annual Strategic Decisions Conference May 29, 2025 3:30 PM ET Corporate Participants Rob Davis - Chairman and Chief Executive Officer Dean Li - Executive Vice President, President of Merck Research Labs Conference Call Participants Courtney Breen - Bernstein Courtney Breen All right. So, we might kick off our conversation with Merck today.
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Merck Proves Why It's Still A Top Pharma Pick
Despite a catastrophic drop in sales of the Gardasil franchise, mainly due to weak demand from China, Merck once again beat consensus EPS and revenue estimates. So, the key contributors whose performance pleasantly surprised me in Q1 2025, and thanks to which Merck's operating income margin remains above 40%, are Vaxneuvance, Winrevair, and Welireg. From its oncology franchise, I highlight Welireg as a 'gem,' whose sales amounted to $137 million in the first three months of 2025, an increase of 61.2% year-on-year.
MRK Down 21% YTD: Should You Buy, Hold or Sell the Stock?
Merck stock lags industry as Keytruda dependency, Gardasil woes in China, and tariff risks cloud outlook despite pipeline strength and new launches.
Should You Buy MRK Stock At $80?
Merck (NYSE:MRK) stock has experienced a significant 22% decline this year, sharply underperforming the broader S&P 500 index, which is down only 1%. This downturn can be attributed to several factors: a lowered guidance for 2025 and growing concerns about the long-term growth prospects of its blockbuster drugs, Keytruda and Gardasil.
Merck: Defensive Yield Meets Long-Term Optionality
The market has largely priced in the 2028 Keytruda patent cliff, with Merck trading at a discount reflecting aggressive revenue erosion assumptions. Merck is actively expanding in oncology, immunology, and vaccines through acquisitions and R&D, offering long-term optionality beyond Keytruda. Gardasil's China-driven slump has limited downside left, with stable ex-China growth and male-use approval offering medium-term recovery potential.
Merck: Undervalued In Light Of Key Risks
Merck & Co. is undervalued, trading at lower multiples than peers, due to concerns over patent expirations and recent financial volatility. Despite modest overall revenue growth, oncology—especially Keytruda—drives strong segment performance, offsetting declines in virology and diabetes products. Management is aggressively investing in R&D and manufacturing expansion, with a robust drug pipeline and significant capital commitments to future growth.
MRK, Daiichi Begin Pivotal Esophageal Cancer Study With ADC Drug
The IDeate-Esophageal01 study is set to evaluate Merck & Daiichi's ADC drug ifinatamab deruxtecan in pre-treated patients with esophageal squamous cell carcinoma.
